Detalles de la búsqueda
1.
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.
N Engl J Med
; 2024 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38767614
2.
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
N Engl J Med
; 389(3): 205-214, 2023 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37272521
3.
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
N Engl J Med
; 389(14): 1263-1272, 2023 Oct 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37792612
4.
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.
N Engl J Med
; 387(25): 2317-2330, 2022 12 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36546624
5.
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
J Allergy Clin Immunol
; 2024 Feb 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38431226
6.
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.
N Engl J Med
; 385(24): 2230-2240, 2021 12 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34879449
7.
Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study.
Respir Res
; 25(1): 107, 2024 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38419035
8.
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
J Am Acad Dermatol
; 90(6): 1190-1199, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38296199
9.
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 400(10356): 908-919, 2022 09 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36116481
10.
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.
Clin Exp Allergy
; 51(7): 915-931, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34037993
11.
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
Ann Allergy Asthma Immunol
; 126(5): 584-592.e1, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33465455
12.
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Lancet
; 394(10209): 1638-1650, 2019 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31543428
13.
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
J Am Acad Dermatol
; 82(6): 1328-1336, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32135208
14.
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
J Am Acad Dermatol
; 83(5): 1282-1293, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32574587
15.
Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.
Allergol Int
; 69(4): 578-587, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32444306
16.
Deterioration of Limb Muscle Function during Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care Med
; 197(4): 433-449, 2018 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29064260
17.
AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung Inhibition of LPS-Induced TNFα with Minimal Systemic Exposure.
J Pharmacol Exp Ther
; 365(3): 567-572, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29549158
18.
Vitamin D rescues impaired Mycobacterium tuberculosis-mediated tumor necrosis factor release in macrophages of HIV-seropositive individuals through an enhanced Toll-like receptor signaling pathway in vitro.
Infect Immun
; 81(1): 2-10, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23071135
19.
Mammalian target of rapamycin inhibition in macrophages of asymptomatic HIV+ persons reverses the decrease in TLR-4-mediated TNF-α release through prolongation of MAPK pathway activation.
J Immunol
; 187(11): 6052-8, 2011 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22025552
20.
Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies.
J Asthma Allergy
; 16: 333-342, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37026112